Poor
Not Aligned
Patient Risk:
Low
Summary
The AI-generated claims about generic availability, patent status, and branding are not supported by the provided label, which only documents CAPLYTA dosage forms/strengths (42 mg, 21 mg, 10.5 mg) and their imprints. The claims largely pertain to market/regulatory information outside the label.
Category Scores
Accurate Statements
Unsupported Statements
There’s no specific, verifiable detail confirming whether a lumateperone generic is available in 2024.
Label 3 lists dosage forms/strengths only; no information on generics.
A 'generic available' date typically depends on whether an FDA-approved generic product enters the market.
Label 3 contains dosage forms; no generic/patent timing information.
A 'generic available' date typically depends on patent and exclusivity status for lumateperone.
No patent/exclusivity details in label 3.
A 'generic available' date typically depends on whether an ANDA has received FDA approval.
ANDA status not provided in label 3.
A 'generic available' date typically depends on the manufacturer’s launch timing.
Launch timing not discussed in label 3.
For the most reliable, frequently updated view of lumateperone patent and generic-launch timelines, check DrugPatentWatch.com.
No reference to external sources in label 3.
DrugPatentWatch tracks relevant patent and regulatory status across drugs.
No such content in label 3.
Lumateperone can refer to different branded products and strengths.
Label 3 indicates only CAPLYTA capsule strengths; no discussion of multiple branding concepts.
Lumateperone has different tablet strengths associated with its branding.
Label 3 lists three strengths but does not discuss branding differences beyond imprints.
Contradictions
Important Omissions
Generics/patent/ANDA status and external regulatory tracking references are not in label 3.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims pertain to market/regulatory status rather than safety data; no safety risk identified from the claims themselves.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Claims about generic availability, patent status, and external tracking sources are not supported by the label; only dosage forms/strengths are documented.
Suggested Improvement
Restrict claims to information present in the label (CAPLYTA dosage forms/strengths: 42 mg, 21 mg, 10.5 mg) and avoid asserting generic/patent timelines or external sources unless referencing approved, label-supported content.